AWM
IONS icon

Abound Wealth Management’s Ionis Pharmaceuticals IONS Stock Holding History

Abound Wealth Management’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-67
Closed -$2.4K – 1208
2023
Q1 		$2.4K Buy
+67
New +$2.52K ﹤0.01% 568

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
TBC
Tweedy, Browne Co Stamford, Connecticut $1.26B AUM 33.88% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Abound Wealth Management's IONS Position: Q2 2023 in Review

Abound Wealth Management sold out of Ionis Pharmaceuticals (IONS) in Q2 2023, closing a stake of 67 shares — an estimated $2.4K sold.

Abound Wealth Management first reported a position in IONS in Q1 2023 and held it in 1 quarter. The position peaked at $2.4K in Q1 2023. 304 funds tracked by Wall St. Rank hold IONS as of Q2 2023.

  • Abound Wealth Management reported no remaining Ionis Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Abound Wealth Management sold 67 Ionis Pharmaceuticals shares in Q2 2023, an estimated $2.4K.
  • Abound Wealth Management first reported a position in Ionis Pharmaceuticals in Q1 2023 and held it in 1 quarter.
  • Abound Wealth Management's Ionis Pharmaceuticals position peaked at $2.4K in Q1 2023.
  • 304 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2023.

Based on Abound Wealth Management's 13F filing for Q2 2023, filed 8 Aug 2024.